Venn Life Sciences Holdings PLC Innovenn commences production at new facilities (5065X)
20 Novembre 2014 - 8:01AM
UK Regulatory
TIDMVENN
RNS Number : 5065X
Venn Life Sciences Holdings PLC
20 November 2014
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Innovenn commences production of Labskin at new state of the art
facilities
Venn Life Sciences (AIM: VENN), a growing Clinical Research
Organisation (CRO) providing clinical trial management and
resourcing solutions to pharmaceutical, biotechnology and medical
device clients, announces that its innovation division, Innovenn,
has commenced production of its pioneering product Labskin at their
new state of the art laboratory facilities in the UK.
Labskin, a human skin equivalent, allows high quality skin
research to be carried out in the sponsors own facilities. Unlike
most skin models, Labskin provides an environment similar to human
skin in that it can house microflora.
The commencement of production at these new facilities marks a
milestone for Innovenn as they have sought to streamline operations
to deal with larger order volumes and a wider geographic
distribution. Innovenn have also recently recruited additional
technical staff to assist with production and order
fulfillment.
Tony Richardson, CEO of Venn Life Sciences commented: "We are
delighted to be able to offer our clients one of the most exciting
skin research products ahead of schedule from our facilities in
York. We will continue to work and build capacity in order to
increase our worldwide distribution of Labskin and the provision of
associated microbiology services."
Enquiries:
Venn Life Sciences Holdings Plc www.vennlifesciences.com
Tony Richardson, Chief Executive Officer Tel: +353 154 99 341
Declan Service, Managing Director Tel: +353 877705506
Orla McGuinness, Marketing Manager
Zeus Capital (Nominated Adviser and Broker)
Ross Andrews/Andrew Jones (Corporate Finance) Tel: 0161 831 1512
Dominic Wilson (Institutional Sales) Tel: 020 7533 7727
Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About InnoVenn
InnoVenn (55.6% owned by Venn) is a market development
accelerator dedicated to rapidly commercialising proven scientific
breakthroughs in the form of products and technologies primarily in
Skin Science. These include Labskin the breakthrough research grade
human skin testing platform as well as the clinically proven
Blemish Control Technology for the professional skincare market.
For more information on Innovenn, visit www.innovenn.co.uk
About Venn Life Sciences Limited
Venn Life Sciences is a Clinical Research Organisation providing
clinical trial management solutions and resourcing solutions to
pharmaceutical, biotechnology and medical device organisations.
With dedicated operations in France, Germany, the Netherlands, the
UK and Ireland and Europe wide representation - Venn specialises in
rapid deployment and management of multisite projects. Venn
recently established an innovation division - Innovenn - focused
primarily on breakthrough development opportunities in Skin
Science.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAVKLFFZFFBFBV
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024